Huma Raises $80 Million Reaching Near-$1 Billion Valuation
This article is for subscribers only.
Huma Therapeutics Ltd. has raised $80 million, valuing the startup at nearly $1 billion in the increasingly crowded health-care AI arena.
The Series D financing for the London-headquartered firm includes investments by drug makers AstraZeneca Plc and Bayer AG, as well as Japan’s Hitachi Ventures and Italy’s Hat Technology Fund, according to Huma Chief Executive Officer Dan Vahdat.